NASDAQ:PRPH ProPhase Labs (PRPH) Stock Price, News & Analysis $0.11 -0.01 (-8.26%) As of 05/15/2026 03:31 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ProPhase Labs Stock (NASDAQ:PRPH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ProPhase Labs alerts:Sign Up Key Stats Today's Range$0.10▼$0.1150-Day Range$0.07▼$0.1552-Week Range$0.07▼$6.66Volume11,814 shsAverage Volume288,225 shsMarket Capitalization$661.82 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview ProPhase Labs, Inc. is a U.S.-based specialty health sciences company that develops, manufactures and markets a range of diagnostic and therapeutic products. The company’s operations span infectious disease testing services, over-the-counter remedies and contract manufacturing for pharmaceutical and consumer health clients. ProPhase Labs leverages both in-house production facilities and distribution networks to bring targeted solutions to market. In its diagnostics division, ProPhase Labs offers laboratory-based testing for respiratory and infectious diseases, employing molecular and immunoassay technologies. The company’s lab services cater to hospitals, clinics and physician practices by providing timely, accurate results that support patient care and public health monitoring. On the therapeutic side, ProPhase Labs markets a portfolio of over-the-counter products designed to relieve symptoms of cold and flu, including nasal inhalers and throat sprays, alongside branded disinfectants and personal care items. ProPhase Labs also provides contract manufacturing and packaging services for third-party health and wellness companies, overseeing formulation, sterile filling and quality-control testing within its U.S. facilities. Through these integrated offerings, the company serves a broad domestic customer base in the healthcare, retail and institutional markets. Management continues to focus on expanding its diagnostic test menu and consumer product lines, leveraging regulatory expertise and manufacturing capabilities to support future growth.AI Generated. May Contain Errors. Read More ProPhase Labs Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks2nd Percentile Overall ScorePRPH MarketRank™: ProPhase Labs scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.5 / 5Analyst RatingSell Consensus RatingProPhase Labs has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageProPhase Labs has received no research coverage in the past 90 days.Read more about ProPhase Labs' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ProPhase Labs are expected to grow in the coming year, from ($1.27) to ($0.56) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ProPhase Labs is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ProPhase Labs is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProPhase Labs has a P/B Ratio of 0.04. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about ProPhase Labs' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for PRPH. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldProPhase Labs does not currently pay a dividend.Dividend GrowthProPhase Labs does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for ProPhase Labs this week, compared to 2 articles on an average week. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, ProPhase Labs insiders have not sold or bought any company stock.Percentage Held by Insiders9.60% of the stock of ProPhase Labs is held by insiders.Percentage Held by Institutions9.45% of the stock of ProPhase Labs is held by institutions.Read more about ProPhase Labs' insider trading history. Receive PRPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProPhase Labs and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PRPH Stock News HeadlinesProPhase Labs Delays Quarterly Financial FilingMay 15 at 7:30 PM | tipranks.comProPhase Labs Reports Year-End 2025 Results, Highlights Accelerating Settlement Activity and Investment-Ready Crown Medical Collections PlatformApril 15, 2026 | globenewswire.com$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s known for playing his cards “close to the vest”… Is going to give you the name and ticker symbol of a company he believes will skyrocket thanks to the coming Starlink IPO…May 17 at 1:00 AM | Paradigm Press (Ad)ProPhase Labs Provides Business Update Highlighting Advancing Crown Medical Collections ActivityMarch 18, 2026 | finance.yahoo.comProPhase Labs Explores Strategic Options for BE-Smart TestFebruary 13, 2026 | tipranks.comProPhase Labs, Inc.: ProPhase Labs Initiates Potential Sale or Strategic Partnership of BE-Smart and Advances Crown Medical Collections InitiativeFebruary 3, 2026 | finanznachrichten.deProPhase Labs Initiates Potential Sale or Strategic Partnership of BE-Smart™ and Advances Crown Medical Collections InitiativeFebruary 3, 2026 | finance.yahoo.comProPhase Labs initiates potential sale or strategic partnership of BE-SmartFebruary 3, 2026 | seekingalpha.comSee More Headlines PRPH Stock Analysis - Frequently Asked Questions How have PRPH shares performed this year? ProPhase Labs' stock was trading at $0.4475 at the beginning of 2026. Since then, PRPH shares have decreased by 75.4% and is now trading at $0.1099. How were ProPhase Labs' earnings last quarter? ProPhase Labs, Inc. (NASDAQ:PRPH) posted its quarterly earnings results on Wednesday, November, 19th. The company reported ($1.60) EPS for the quarter, missing analysts' consensus estimates of ($1.10) by $0.50. The company earned $0.88 million during the quarter, compared to the consensus estimate of $5.69 million. ProPhase Labs had a negative net margin of 825.01% and a negative trailing twelve-month return on equity of 482.05%. Read the conference call transcript. When did ProPhase Labs' stock split? Shares of ProPhase Labs reverse split before market open on Monday, December 22nd 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Sunday, December 21st 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of ProPhase Labs? Shares of PRPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ProPhase Labs own? Based on aggregate information from My MarketBeat watchlists, some other companies that ProPhase Labs investors own include Meta Platforms (META), Pfizer (PFE), Valero Energy (VLO), Catalyst Pharmaceuticals (CPRX) and Energy Transfer (ET). Company Calendar Last Earnings11/19/2025Today5/17/2026Next Earnings (Estimated)5/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (5m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 PRPH's financial health is in the Red zone, according to TradeSmith. PRPH has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PRPH CIK868278 Webwww.prophaselabs.com Phone(215) 345-0919Fax215-345-5920Employees130Year Founded1981Profitability EPS (Trailing Twelve Months)($3.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$53.36 million Net Margins-825.01% Pretax Margin-680.20% Return on Equity-482.05% Return on Assets-88.90% Debt Debt-to-Equity Ratio0.14 Current Ratio0.14 Quick Ratio0.14 Sales & Book Value Annual Sales$5.06 million Price / Sales0.13 Cash FlowN/A Price / Cash FlowN/A Book Value$2.46 per share Price / Book0.04Miscellaneous Outstanding Shares6,022,000Free Float5,444,000Market Cap$661.82 thousand OptionableOptionable Beta0.15 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:PRPH) was last updated on 5/17/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProPhase Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProPhase Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRPH Stock Alerts